Search results
Showing 106 to 118 of 118 results for blood transfusion
What is the clinical and cost effectiveness of preoperative optimisation clinics for older people?
effects from daily iron. This has the potential to reduce the need for blood transfusions and improve surgical outcomes for...
effects from daily iron. This has the potential to reduce the need for blood transfusions and improve surgical outcomes for...
effects from daily iron. This has the potential to reduce the need for blood transfusions and improve surgical outcomes for...
Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.
Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.
Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (HTG124)
Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.
View recommendations for HTG124Show all sections
Sections for HTG124
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance.
Patients with rare blood disorders to receive new treatment option, says NICE
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.